Syros Pharmaceuticals, Inc.'s (NASDAQ:SYRS) high institutional ownership speaks...

Published on 21 Jun 2024 on Simply Wall St. · via Yahoo Finance

Key Insights Significantly high institutional ownership implies Syros Pharmaceuticals' stock price...

Read the rest of the article

Start tracking your investments with Statfolio

Revenue: No revenue recognized in Q3 2024, compared to $3.8 million in Q3 2023. R&D Expenses: $20...

GuruFocus.com · via Yahoo Finance 1 Nov 2024

Revenue: No revenue recognized in Q2 2024, compared to $2.8 million in Q2 2023. R&D Expenses: $22...

GuruFocus.com · via Yahoo Finance 9 Oct 2024

On the date of the purchase, shares of Syros Pharmaceuticals Inc were priced at $1.61, leading to...

GuruFocus.com · via Yahoo Finance 22 Sep 2024

Syros Pharmaceuticals Inc (NASDAQ:SYRS) is a biopharmaceutical company focused on the development...

GuruFocus.com · via Yahoo Finance 22 Sep 2024

Key Insights Significantly high institutional ownership implies Syros Pharmaceuticals' stock pric...

Simply Wall St. · via Yahoo Finance 21 Jun 2024

The market expects Syros Pharmaceuticals, Inc. (SYRS) to deliver a year-over-year decline in earn...

Zacks via Yahoo Finance 1 May 2024

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Q4 2023 Earnings Call Transcript March 27, 2024 Syros P...

Insider Monkey via Yahoo Finance 29 Mar 2024

Syros Pharmaceuticals, Inc. SYRS shares have skyrocketed 200% in the past three months compared w...

Zacks via Yahoo Finance 22 Jan 2024

While "the trend is your friend" when it comes to short-term investing or trading, timing entries...

Zacks via Yahoo Finance 15 Jan 2024

Momentum investing revolves around the idea of following a stock's recent trend in either directi...

Zacks via Yahoo Finance 15 Jan 2024